Letrozole add-on in the Treatment of Cesarean Scar Pregnancy

• Status: Active, not recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: Female

Summary

It is hypothesized that the inhibition of estradiol production by letrozole may interfere with physiological effects of progesterone necessary to maintain the pregnancy. There is no reference treatment of cesarean scar pregnancy (CSP) as the limited number of cases precludes the extrapolation of results. In our center we successfully use two-step treatment with methotrexate (MTX) followed by hysteroscopic removal of products of conception (POC). The time in between is needed to achieve a decrease in the trophoblast's vital potential (B-hCG fall) and its vascularization. Additional administration of letrozole could further reduce the vital potential of the pregnancy, eliminating the need for another dose of MTX, resulting in faster healing and lower rate of complications.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jagiellonian University
• Treatments: Letrozole

Criteria

Inclusion Criteria:

• CSP confirmed on pelvic ultrasound

• consent of the Bioethics Committee for termination of CSP

• increasing B-hCG concentrations

Exclusion Criteria:

• heterotopic pregnancy

• decreasing B-hCG concentrations